Palisade Bio, Inc. Share Price
PALIPalisade Bio, Inc. Stock Performance
Open $1.96 | Prev. Close $1.89 | Circuit Range N/A |
Day Range $1.96 - $2.27 | Year Range $0.53 - $2.85 | Volume 6,34,094 |
Average Traded $2.16 |
Palisade Bio, Inc. Share Price Chart
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Palisade Bio, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
29-Jun-26 | $1.96 | $2.24 | +0.00% |
29-Jun-26 | $1.96 | $2.24 | +18.52% |
26-Jun-26 | $1.82 | $1.89 | +5.29% |
25-Jun-26 | $1.93 | $1.79 | -6.51% |
24-Jun-26 | $1.90 | $1.92 | -1.03% |
23-Jun-26 | $1.84 | $1.94 | +6.01% |
22-Jun-26 | $1.93 | $1.83 | -2.66% |